The completion of enrollment removes a key execution risk for the ACHIEVE trial. The next major catalyst is the Q1 2027 topline data readout. Traders should monitor for any early efficacy signals or safety updates between now and then, as well as enrollment progress in the confirmatory Phase 3 HARMONIA trial.
Price Chart
Executive Summary
Dyne Therapeutics announced full enrollment (71 participants) of the registrational expansion cohort in its Phase 1/2 ACHIEVE trial of z-basivarsen for myotonic dystrophy type 1 (DM1). Topline data is expected in Q1 2027, with a potential BLA submission for Accelerated Approval in Q3 2027 and a potential U.S. launch in H1 2028. This is a key derisking milestone for the company's lead asset, but the stock impact will depend on the actual topline data readout next year.
Key Facts
- Registrational expansion cohort (REC) of Phase 1/2 ACHIEVE trial fully enrolled with 71 participants.
- Topline data from the REC planned for Q1 2027.
- Potential BLA submission for U.S. Accelerated Approval in Q3 2027.
- Potential U.S. launch of z-basivarsen expected in H1 2028, assuming FDA Priority Review and approval.
- Primary endpoint for the REC is change from baseline in middle finger myotonia measured by vHOT at 6 months vs placebo.
- Z-basivarsen has Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA.
- DM1 affects ~40,000 people in the U.S. and ~55,000 in the EU with no approved disease-modifying treatments.
Financial Impact
No financial data provided in the filing. The event is a clinical milestone with no revenue or earnings impact yet.
Risk Factors
- Topline data in Q1 2027 may fail to meet the primary endpoint or show insufficient efficacy for Accelerated Approval.
- FDA may not grant Accelerated Approval or Priority Review, delaying the potential launch timeline.
- Competing therapies for DM1 could emerge, reducing z-basivarsen's market opportunity.
- Cash burn rate and need for future financing before potential commercialization in 2028.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254597 |
| Document: dyn-ex99_1.htm | 0001193125-26-254597 |
| Document: 0001193125-26-254597-index-headers.html | 0001193125-26-254597 |
| Document: 0001193125-26-254597-index.html | 0001193125-26-254597 |
| Document: 0001193125-26-254597.txt | 0001193125-26-254597 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.20 (+41.87%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.20 (−41.87%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.20 (+40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.20 (−40.86%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.20 (−40.92%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.20 (+34.51%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.20 (−35.18%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.20 (−30.24%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.20 (+31.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access